Metformin in everyday clinical practice

Grzegorz Dzida; Piotr Gajda; Dorota Kuzemko

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

2/2017
vol. 3

Send email

Copy url:

abstract:

Review paper

Metformin in everyday clinical practice

Grzegorz Dzida

,

Piotr Gajda

,

Dorota Kuzemko

Online publish date: 2017/05/18

View full text Get citation

Type 2 diabetes is a serious social problem. In pharmacotherapy of the disease, the recommended drug of the first choice is metformin, which has been available on the market for 60 years now. The main effect of metformin is antihyperglycemic activity through several mechanisms of action. Metformin exerts non-glycemic effects as well. As a result of long-lasting treatment, metformin substantially reduces the cardiovascular risk. The new therapeutic indication for metformin is prediabetes.

keywords:

Metformin in everyday clinical practice

Grzegorz Dzida , Piotr Gajda , Dorota Kuzemko

metformin, biguanides, type 2 diabetes, prediabetes

Grzegorz Dzida

,

Piotr Gajda

,

Dorota Kuzemko